Holen Sie sich die Stockscreener-App
35.42
0.77%
0.27
Schlusskurs vom Vortag:
$35.15
Offen:
$35.1
24-Stunden-Volumen:
4.00M
Relative Volume:
1.12
Marktkapitalisierung:
$15.31B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
15.40
EPS:
2.3
Netto-Cashflow:
$827.02M
1W Leistung:
-2.96%
1M Leistung:
-2.56%
6M Leistung:
+8.09%
1J Leistung:
+25.34%
1-Tages-Spanne:
$35.05
$35.65
1-Wochen-Bereich:
$34.84
$36.94
52-Wochen-Spanne:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.42 | 15.20B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Empowered Funds LLC Buys New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Completes $2 Billion Senior Notes Offering - TipRanks
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
Gainers Report: Will Royalty Pharma plc outperform the market in YEARMarket Sentiment Summary & Stock Timing and Entry Methods - خودرو بانک
Royalty Pharma stock price target raised to $38 from $37 at UBS - Investing.com UK
Pullback Watch: Is Royalty Pharma plc stock undervalued right nowWeekly Trade Analysis & Consistent Return Investment Signals - خودرو بانک
Royalty Pharma (RPRX) PT Raised to $38 at UBS, But Firm on Sidelines Due to Structural Issues - StreetInsider
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts - Yahoo Finance
Royalty Pharma Plc's (NASDAQ:RPRX) Prospects Need A Boost To Lift Shares - 富途牛牛
Aug Chart Watch: Is Royalty Pharma plc stock technically oversoldTrade Risk Assessment & Community Verified Trade Alerts - خودرو بانک
Pacific Capital Partners Ltd Cuts Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Petrus Trust Company LTA Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Signal Recap: Will Royalty Pharma plc be affected by tariffs2025 Earnings Surprises & AI Powered Market Entry Strategies - خودرو بانک
USS Investment Management Ltd Sells 42,500 Shares of Royalty Pharma PLC $RPRX - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Holdings in Royalty Pharma PLC $RPRX - MarketBeat
EP Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Uniplan Investment Counsel Inc. Purchases 11,904 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Stake Lessened by Baird Financial Group Inc. - MarketBeat
TD Cowen reiterates Buy rating on Royalty Pharma stock, citing strong metrics - Investing.com Nigeria
Royalty Pharma: Investor Day Upside (NASDAQ:RPRX) - Seeking Alpha
TD Cowen Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Alliancebernstein L.P. Purchases 86,873 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation - MarketScreener
Volatility clustering patterns for Royalty Pharma plcCEO Change & AI Enhanced Market Trend Forecasts - Newser
Why Royalty Pharma plc is moving todayMarket Risk Report & Smart Allocation Stock Tips - Newser
Punch & Associates Investment Management Inc. Purchases 101,390 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Transcript : Royalty Pharma plcAnalyst/Investor Day - MarketScreener
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program - Insider Monkey
Royalty Pharma prices $2B senior unsecured notes - MSN
Royalty Pharma Expects At Least Mid-teens Average Annual Total Shareholder Return Over 2025-2030. - Nasdaq
Royalty Pharma : Investor Day Presentation - MarketScreener
Royalty Pharma : Role of Royalties in Funding Biopharma Innovation - MarketScreener
Royalty Pharma targets mid-teens annual shareholder return over next 5 years - MarketScreener
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation - MarketScreener
$4.7 Billion Growth Target: Royalty Pharma Plans to Double Biopharma Funding as Market Expands Rapidly - Stock Titan
Royalty Pharma PLC $RPRX Stock Position Lifted by AQR Capital Management LLC - MarketBeat
Nomura Holdings Inc. Buys New Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma and Deloitte Release Landmark Report on Biopharma Royalty Market Insights and Trends - Quiver Quantitative
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market - MarketScreener
87% of Pharma Leaders Embrace Royalty Funding: Royalty Pharma's Groundbreaking Industry Study Reveals Shift - Stock Titan
Amundi Sells 1,316,620 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Acquires 56,419 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cutter Capital Management LP Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Panagora Asset Management Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma’s $2 Billion Debt Raise Could Be a Game Changer for RPRX - simplywall.st
Is Royalty Pharma plc likely to announce a buyback2025 Price Targets & AI Enhanced Trade Execution Alerts - 뉴스영
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):